MFFIA
GILD icon

McIntyre, Freedman & Flynn Investment Advisers’s Gilead Sciences GILD Stock Holding History

McIntyre, Freedman & Flynn Investment Advisers’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Hold
2,158
– – 0.16% 66
2026
Q1 		$301K Hold
2,158
– – 0.17% 64
2025
Q4 		$265K Hold
2,158
– – 0.17% 69
2025
Q3 		$240K Buy
+2,158
New +$245K 0.14% 67

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

McIntyre, Freedman & Flynn Investment Advisers's GILD Position: Q2 2026 in Review

McIntyre, Freedman & Flynn Investment Advisers held its Gilead Sciences (GILD) position steady in Q2 2026 at 2,158 shares worth $273K. The position accounts for 0.16% of the portfolio, ranked #66.

McIntyre, Freedman & Flynn Investment Advisers first reported a position in GILD in Q3 2025 and has held it in 4 quarters since. The position peaked at $301K in Q1 2026. 1,815 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • McIntyre, Freedman & Flynn Investment Advisers held 2,158 shares of Gilead Sciences worth $273K as of Q2 2026.
  • McIntyre, Freedman & Flynn Investment Advisers left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.16% of McIntyre, Freedman & Flynn Investment Advisers's portfolio in Q2 2026, its #66 holding.
  • McIntyre, Freedman & Flynn Investment Advisers first reported a position in Gilead Sciences in Q3 2025 and has held it in 4 quarters since.
  • McIntyre, Freedman & Flynn Investment Advisers's Gilead Sciences position peaked at $301K in Q1 2026.
  • 1,815 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.